Abstract:Abstract Colorectal cancer (CRC) is the third most common cancer and a major cause of cancer related death. Colitis-associated colorectal carcinoma (CAC) is a type of CRC that develops in patients with inflammatory bowel disease (IBD), and is associated with chronic, idiopathic intestinal inflammation. While the underlying cause(s) are poorly understood, environmental factors including high fat diets and aberrant intestinal immune responses contribute to disease progression. Bile acid (BA) overproduction is implicated in diarrhea associated with IBD and CAC. As early sensors of dietary status, BAs are critical mediators of gut inflammation and immunity, in part through their ability to affect the activity of the Farnesoid X Receptor (FXR). FXR is considered the master regulator of BA homeostasis, also a key modulator of the pro- and anti-inflammatory responses in the intestinal epithelium, whose function severely compromised in both CAC patients and in AOM/DSS mouse model. Here, we show that inflammation-induced epithelial abnormalities altered the BAs profile, given the role of the crypt-villus architecture in establishing a BA gradient necessary for homeostasis. In addition, AOM/DSS treatment enhanced immune cell infiltration, as well as induced the formation of massive tumors in the colon. Given that intestinally-restricted FXR agonist FexD can reduced tumorigenesis in APCmin/+ mice, we also treated AOM/DSS mice with FexD. Notably, FexD activated FXR signaling pathway and restored BA homeostasis. Further, it reduced fecal bleeding, intestinal permeability, and decreased serum levels of the late carcinogenesis markers CEA and CA19. Treatment of FexD also resulted in a smaller spleen and reduced pro-inflammatory cytokine levels such as IL17 and IL6. The present study highlights the role of FXR in inflammation induced colon cancer, opening new therapeutic avenues for the treatment of CAC. Citation Format: Ting Fu, Ronald Evans. The bile acid receptor FXR suppress colitis-induced colon cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 396.

Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer

Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders

The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function and Innate Immunity

Farnesoid X receptor: a potential therapeutic target in multiple organs

FXR: structures, biology, and drug development for NASH and fibrosis diseases

The pathophysiological function of non-gastrointestinal farnesoid X receptor.

Bile acid nuclear receptor FXR and digestive system diseases

Farnesoid X receptor mediates macrophage-intrinsic responses to suppress colitis-induced colon cancer progression

The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer

FXR agonists for colorectal and liver cancers, as a stand-alone or in combination therapy

Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease

The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis

[Progress in the Role of Farnesoid X Receptor in Metabolic Regulation and Tumor Cell Proliferation].

Pleiotropic roles of FXR in liver and colorectal cancers

Farnesoid X Receptor (FXR): Structures and Ligands.

Update on FXR Biology: Promising Therapeutic Target?

Discovery of farnesoid X receptor and its role in bile acid metabolism

FXR Modulators for Enterohepatic and Metabolic Diseases.

Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease

Abstract 396: The bile acid receptor FXR suppress colitis-induced colon cancer

Intestinal microbiota-farnesoid X receptor axis in metabolic diseases